Sangamo Therapeutics (SGMO) Tops Q4 EPS by 37c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of $0.04, $0.37 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $54.9 million versus the consensus estimate of $15.54 million.

Financial Guidance for 2020:

On a GAAP basis, Sangamo expects total operating expenses to be in the range of $270 to $285 million in 2020, which includes non-cash stock-based compensation expense of approximately $25 million.

Non-GAAP total operating expenses, excluding expected non-cash stock-based compensation expense of approximately $26 million, are expected to be in the range of $245 to $260 million

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance